Morgan Stanley acquired 140,100 shares of NOVOSENSE (02676) (H shares) on September 24, 2026, via an off-exchange transaction, representing an increase in shares over which it may exercise its right to rehypothecate or dispose of.
Prior to the acquisition, Morgan Stanley's long position in NOVOSENSE was 973,800 shares, representing 4.84%; following the acquisition, the holding changed to 1.11 million shares, with the long position ratio rising to 5.54%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.